NCT02957864View on ClinicalTrials.gov

Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide

PHASE4UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

September 30, 2020

Conditions
Renal Insufficiency,ChronicHivTherapeutic Agent Toxicity
Interventions
DRUG

tenofovir alafenamide

DRUG

abacavir

Trial Locations (5)

Unknown

RECRUITING

Ziekenhuis Rijnstate, Arnhem

1066EC

RECRUITING

MC Slotervaart, Amsterdam

1091AC

NOT_YET_RECRUITING

OLVG, Amsterdam

3000CA

RECRUITING

Erasmus MC, Rotterdam

3079DZ

RECRUITING

Maasstad ziekenhuis, Rotterdam

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Erasmus Medical Center

OTHER

NCT02957864 - Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide | Biotech Hunter | Biotech Hunter